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Introduction
Tuberculosis (TB) still accounts for the highest mortality from any infectious 
diseases worldwide, even surpassing HIV/AIDs.[1] Uganda has an incidence of TB 
of about 20/100,000 population where the prevalence of Multi-Drug Resistant 
TB (MDR –TB) in 2015 was estimated to be 1.6% among newly diagnosed TB 
cases and 12% among previously-treated cases.[2]
Drug resistant TB poses a threat to effective control due to the difficulties in 
diagnosis, the requirement for chemotherapy for up to two years, increased 
cost (up to 100 times more expensive than drug susceptible TB) and the use of 
more toxic second line drugs that are associated with increased adverse effects.[3] 
The World Health Organization (WHO) 2016 DR-TB treatment Guidelines 
included recommendations on the use of a standardized shorter treatment 
regimen (sSTR) of 9 -12 months for patients with Rifampicin Resistant (RR)/
MDR-TB which includes the injectable drugs. 
The WHO 2019 guidelines recommend that the modified bedaquiline-based 
therapy (a drug regimen which includes bedaquiline as the major drug), all oral 
shorter regimens (mSTR) may be used with close monitoring. Some groups of 
patients can still be put on the sSTR which includes the injectable drugs.[4]
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Abstract
Introduction: Second-line injectable therapy using aminoglycosides (AG) like 
kanamycin, amikacin or capreomycin is associated with irreversible hearing 
loss. We aimed to determine the incidence and predictors of hearing loss 
among patients with drug resistant tuberculosis (DR-TB) who received AG.
Method: This was a retrospective cohort study conducted at the tuberculosis 
treatment unit of Mbarara Regional Referral Hospital (MRRH). All adult 
patients with a diagnosis of DR-TB between March 2016 and December 
2019 were candidates for inclusion in the study. Hearing loss was defined as a 
hearing threshold of >20 decibels (dB) at any test frequency in at least one ear. 
The incidence and predictors of hearing loss were analysed using multivariable 
Cox model. A p-value of ≤0.05 was considered as statistically significant. Data 
analysis was done using STATA version 13.
Results: The estimated rate of developing hearing loss was 107 per 1000 
person months. Thirty-seven (52.9%) of 70 DR-TB patients experienced 
some degree of hearing loss, of which 25 (67.6 %) developed mild, 5 (13.5%) 
moderate, and 3 (8.1%) severe hearing loss. Male sex (HR 2.05, CI 1.03-4.10, 
p-value 0.041), increasing age (HR.5.17, CI 1.42-18.87, p-value 0.013) and 
high BMI (HR 3.31, CI 1.15 - 9.53, p-value 0.026) were significant predictors 
of new onset of hearing loss. 
Conclusion: The incidence of hearing loss among DR-TB patients was high, 
with the majority having a mild hearing loss. Patients who were male, older, 
overweight and/or obese were more likely to develop AG-induced hearing loss. 
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At least 60% of patients on MDR-TB therapy will 
experience adverse events.[5] Amongst the most serious 
side effects is irreversible ototoxicity which is caused by 
injectable second line agents,[6] that are administered for 
a minimum period of six months as per the guidelines. 
Amikacin, kanamycin and capreomycin are ototoxic 
mainly through the loss of cochlear and/or vestibular 
sensory hair cells.[7] The irreversible destruction of sensory 
cells in the cochlea leads to permanent hearing loss. It 
begins with the basal cochlea outer hair cells (responsible 
for high frequency sound) and then spreads to the 
apex (responsible for low frequency sound). Reactive 
oxygen species (free radicals) acting as mediators of the 
aminoglycoside (AG) toxicity appear to trigger cell death. [8]
In 2016 the Ugandan national guidelines for the treatment 
of DR-TB recommended the use of a bedaquiline-based 
injection-free shorter treatment regimen (the ‘modified 
shorter regimen’, mSTR), but based on the severity of 
the disease and the eligibility criteria for the mSTR, most 
groups of patients are still being put on the injection-
based regimen. There are limited data in our setting on 
the ototoxic effect of these injectable drugs among the 
DR-TB patients. This study focused on the incidence and 
predictors of hearing loss among DR-TB patients treated 
with the injectable AG based regimen.
Method
This was a retrospective cohort study, which aimed to 
determine the incidence and predictors of hearing loss in 
DR-TB patients, it was conducted in Mbarara Regional 
Referral Hospital TB unit in south-western Uganda. We 
used a retrospective cohort of 118 participants who were 
treated with injectable AG-based regimen between March 
2016 and December 2019 who had received AG for at 
least six months. Patients with pre-existing hearing loss 
or without baseline and at least one follow-up audiometry 
report were excluded, leaving 70 participants whose 
information we analysed.
Hearing was tested at 125Hz, 250Hz, 500Hz, 1000Hz, 
2000Hz, 4000Hz and 8000Hz frequencies. Hearing loss 
was defined as a hearing threshold of >20 decibels (dB) 
at any test frequency in at least one ear. Hearing was 
measured by averaging the hearing thresholds at each visit 
for each ear separately. Hearing loss was categorized into 
mild (21 – 40 dB), moderate (41 – 70 dB), severe (71 – 90 
dB) and profound (>=91 dB). 
Data were entered into Microsoft Excel version 10 and 
imported into STATA version 13. Baseline characteristics 
and degree of hearing loss were described in frequencies 
and percentages. We took the point of hearing loss to 
be at the first observation of hearing loss. Incidence rate 
for hearing loss per 1000 person-months were defined as 
the number of patients with hearing loss divided by the 
Characteristics N=70 (%)
Male sex: 47 (67.1)
Age (years):
15 – 30 18 (25.7)
31 – 45 36 (51.3)
46 and above 16 (22.9)
Body Mass Index (kg/m2):
Normal (18.5 – 24.9) 39 (55.7)
Underweight (<18.5) 19 (27.1)
Overweight/Obese (>25) 4 (5.7)
Missing 8 (11.4)
History of smoking 5 (7.1)
History of alcohol consumption* 24 (34.3)
Positive HIV status 44 (62.9)
History of previous TB infection 27 (38.6)





12-15.5g/dl for females and 
13.5-17.5g/dl for males 47 (67.1)
Anaemic
<12.0g/dl for females and
 <13.5g/dl for males
23 (32.9)
Creatinine:











Table 1. Baseline characteristics
*Any amount of alcohol
person-months at risk of hearing loss. We calculated the 
hazard ratios (HRs) and 95% confidence intervals (CIs) 
using Cox proportional hazards regression analysis. We 
checked the assumptions of the Cox model graphically 
and with statistical tests.
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Results
We extracted 118 files for patients who were treated for 
DR-TB from the TB record centre. Eighteen patients 
had no audiogram records, 14 had no baseline audiogram 
and 16 had no follow-up audiograms, so 70 patients were 
enrolled, all of them were assessed on a monthly basis 
until the end of the sixth month. There were 47 (67.1%) 
males.  Fifty-one percent were aged between 31 – 45 
years; 44 (62.9%) were HIV positive and 61 (87.1%) 
were on kanamycin. Twenty-nine (41.4%) had high 
gene x-pert severity (i.e., high load of Mycobacterium 
tuberculosis complex detection in Xpert) and 54 (77.1%) 
had paucibacillary smear severity (i.e., low bacterial load 
of Mycobacterium tuberculosis in the sputum smear). 
The baseline characteristics are shown in Table 1.
Twenty-five patients (67.6%) developed mild, five 
(13.5%) moderate, three (8.1%) severe and four (10.8%) 
mixed (mild/ moderate) hearing loss (Table 2). Twenty-
five patients (67.6%) had bilateral and 12 (32.4%) had 
unilateral hearing loss (8 in the right ear and 4 in the left 
ear).
The estimated rate of developing hearing loss was 107 per 
1000 person months (CI 77 - 147); the minimum time 
for developing hearing loss was two months and the mean 
was four months (as shown in Kaplan Meier curve - Figure 
1). The cumulative incidence over a period of six months 
was 52.9% (37 out of 70 patients developed hearing loss).
In the adjusted multivariable Cox model, male sex, older 
age and high BMI ≥25kg/m2 were associated significantly 
with hearing loss (Table 3). 
Discussion
Our study showed a hearing loss incidence of 53% after 
the injectable phase which is similar to the study of Harris 
et al in South Africa which found 58% hearing loss among 
their cohort.[9] This is probably because of the similarities 
in the patients’ characteristics. In our study, however, 
HIV infection did not predict hearing loss during DR-TB 
treatment, which conflicts with the finding of Harris et 
al[9] who demonstrated a strong positive association with 
HIV infection.
Characteristics AHR (95% CI) p-value
Sex:   
Female
Male 2.05 (1.03-4.10) 0.041
Age (years):
15 – 30  
31 – 45 5.17 (1.42 - 18.87) 0.013
46 and above 4.85 (1.30 - 18.27) 0.020
Regimen:   
Capreomycin
Kanamycin 0.53 (0.20 - 1.40) 0.201
Previous TB:   
No
Yes 0.77 (0.39 - 1.50) 0.428
HIV status:   
Negative
Positive 0.87 (0.36 - 2.13) 0.765
BMI (kg/m2):   
Normal (18.5 – 24.9)
Underweight (<18.5) 1.10 (0.92 - 4.24) 0.081
Overweight/Obese 
(≥25)
3.31 (1.15 - 9.53) 0.026
Creatinine:
Normal 
(0.6 – 1.1 mg/dl)
High 0.73 (0.13 – 4.01) 0.713
Gene X.pert Severity:
Low
High 0.96 (0.41 – 2.23) 0.938
History of alcohol 
consumption*:
No
Yes 1.42 (0.66 – 3.10) 0.371
Smoking History:
No
Yes 2.70 (0.71 – 10.12) 0.146
Key: AHR: Adjusted Hazard Ratio, CI: Confidence Interval
*Any amount of alcohol
Table 3. Predictors of hearing loss
Degree of hearing loss (>20dB) n (%)
Bilateral mild hearing loss (21 – 40dB) 25 (67.6)
Bilateral moderate hearing loss (41 – 70dB) 5 (13.5)
Bilateral severe hearing loss (71 – 90dB) 3 (8.1)
Mixed hearing loss* (mild and moderate) 4 (10.8)
Table 2. Degree of hearing loss
*Means the patient’s degree of hearing loss in left ear is different 
from the loss in the right ear 
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In our study male sex, increasing age and high BMI 
predicted new onset hearing loss.  Sharma et al also found 
that males were more likely to develop hearing loss than 
females.[10]  
Hong et al. in South Africa also reported that older age 
and obese patients are at a higher risk of developing 
hearing loss.[11] Ageing leads to a decrease in hair cells 
in the cochlea and reduction in endogenous protective 
mechanisms such as antioxidants which may increase the 
susceptibility to ototoxic effects.[12] Obesity may lead to 
hearing loss as adipose tissue secretes pro-inflammatory 
cytokines causing inflammation and end-organ damage.
[13]
We also found that 67.6% of our cohort developed mild 
hearing loss. A prospective study of DR-TB patients 
treated with injectable AG in Pakistan reported that 60% 
of their patients developed mild hearing loss.[14] However, 
our study might have underestimated the degree of 
occurrence of hearing loss because of missing follow-up 
audiograms. In another prospective study in Zambia, 46% 
of patients developed severe hearing loss at the end of the 
AG treatment which is much higher than our 8.1%.[15] 
The prospective nature of their study may have facilitated 
regular audiometry checks throughout the study period.
Conclusion and recommendation
Over half of the DR-TB patients in our study developed a 
degree of hearing loss after six months of treatment. The 
majority developed mild hearing loss and the minimum 
time for the occurrence of hearing loss was two months. 
Male sex, older age, and overweight (BMI>=25 m2) 
predicted hearing loss. 
Therefore, based on our findings, we advocate the use of 
the new non-aminoglycoside medicines e.g., bedaquiline. 
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